Fair Value Calculator Fair Value Calculator
EN DE

TRIOMERC (TRIOMERC) Fair Value & Analysis

IN · Market cap ₹138M

T TRIOMERC TRIOMERC · BSE
Price₹2.03
Fair Value₹0.6700
Upside-67.0%
Quality67/100
Watch TRIOMERC for free — get notified when fair value or trend changes. Watch for free
Evidence: Low Range ₹0.4400 – ₹0.8400

Fair value as of: Jul 6, 2026

From 1 valuation models · updated today

Share price −6.9% over the past month.

Price vs Fair Value (12 months)

₹2.28 ₹0.5500 Fair Value ₹0.6700 Jul 2025 Jul 2026

12‑month range ₹0.5500 – ₹2.28 · fair‑value band ₹0.4400 – ₹0.8400 · the ₹2.03 price screens above the ₹0.6700 fair value. As of Jul 6, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

TRIOMERC (TRIOMERC) currently trades at ₹2.03, while our model-based Fair Value estimate is ₹0.6700 — implying the stock looks roughly 67.0% overvalued today. We read business quality at 67/100 (solid quality). Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

Over the trailing twelve months, TRIOMERC generated revenue of ₹27.6M at a net margin of -2.0%. It earns a return on equity of -0.2%. Net debt stands at ₹13.2M. Fundamentals as of Jul 6, 2026

Our scenario range runs from ₹0.4400 (bear case) to ₹0.8400 (bull case); at ₹2.03, the current price sits above that range. The share trades about 11% below its 52-week high and 283% above its 52-week low, currently above its 200-day average.

Key figures & financial health

Revenue (TTM) ₹27.6M
Revenue growth (YoY) +1,419%
Net margin -2.0%
Return on equity -0.2%
Free cash flow −₹36.8M FY2026
Operating margin -5.7%
More key figures
EPS (TTM) ₹-0.0100
EPS growth (YoY) +105%
Net debt ₹13.2M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

TRIOMERC reported revenue of ₹27.6M in FY2026 versus ₹52.5M in FY2022, a compound −14.9%/yr. Reported net income was −₹536K in FY2026.

Revenue −14.9%/yr
FY22 ₹52.5M
FY23 ₹45.9M
FY24 ₹32.4M
FY25 ₹16.5M
FY26 ₹27.6M
Net income
FY22 −₹4.6M
FY23 −₹1.0M
FY24 −₹2.2M
FY25 −₹542K
FY26 −₹536K

Is TRIOMERC fairly valued? → Check now

🧮 Run the numbers yourself — free valuation calculators
📤 Share or link this analysis
🔗 Embed on your site (free fair-value badge)

Paste this into your site or blog — it shows the current fair value and links back here (free, and welcome):

Cite: Fair Value Calculator (2026). "TRIOMERC Fair Value". https://www.fairvalue-calculator.com/stock/TRIOMERC

Explore undervalued stocks

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap Stocks

Frequently asked questions

Is TRIOMERC (TRIOMERC) undervalued?
As of Jul 6, 2026, our model estimates a fair value of ₹0.6700 versus a price of ₹2.03 — about −67% (overvalued). Model-based estimate, not financial advice.
What is the fair value of TRIOMERC?
Our model-based fair value for TRIOMERC is ₹0.6700 (as of Jul 6, 2026), built from audited fundamentals. The current price is ₹2.03.
What is the quality score of TRIOMERC?
TRIOMERC has a Quality Score of 67/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the revenue of TRIOMERC (TRIOMERC)?
TRIOMERC reported trailing-twelve-month revenue of about ₹27.6M (latest available figure, as of Jul 6, 2026).
What is the net profit margin of TRIOMERC?
The net profit margin of TRIOMERC is about -2.0%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.